drugset / Trial / NCT02389790

Extension Study of MT-1303 in Subjects With Crohn's Disease

NCT02389790

Phase 2 Completed 46 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of the study are: -To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease(CD)

Timeline

Start
2015-08
Primary completion
2017-08
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject amiselimod Small molecule

Indications